SavedAdd your journal

Journals / Endoskopi Gastrointestinal / 2017 / Cilt: 25 Sayı: 2

Dabigatran-induced esophageal ulcer

Dabigatrana bağlı özofagus ülseri

Hakan Ümit ÜNAL
Özlem SAYGILI
Murat SARUÇ
Pages
47–48
Publication Date
2017-08-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present study, we report a case of dabigatran-induced esophageal ulcer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dabigatran, which has an anticoagulant effect by inhibiting the action of thrombin, is a prodrug.
📊
Key Findings & Data:An advantage of this drug over warfarin is that it does not require routine laboratory monitoring and dose adjustments.
💡
Conclusion & Impact:In the present study, we report a case of dabigatran-induced esophageal ulcer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dabigatran · ilaca bağlı özofageal ülser · antikoagülan etki

Abstract

Dabigatran, which has an anticoagulant effect by inhibiting the action of thrombin, is a prodrug. An advantage of this drug over warfarin is that it does not require routine laboratory monitoring and dose adjustments. However, adverse effects on the gastrointestinal system are more common in patients using dabigatran than in patients using warfarin. In the present study, we report a case of dabigatran-induced esophageal ulcer.

Özet

Dabigatran trombin inhibisyonu yaparak antikoagülan etki gösteren bir ön ilaçtır. Rutin labovatuar takibi ve doz titrasyonu gerektirmemesi varfarine göre kullanım avantajı sağlanken, gastrointestinal sistem üzerine daha sık yan etki oluşturması önde gelen dezavantajlarındandır. Bizim vakamız, dabigatran kullanımına bağlı gelişen özofagus ülser hastasıdır.

🔖

Cite This Article

ÜNAL, H. Ü., SAYGILI, Ö., SARUÇ, M. (2017). Dabigatran-induced esophageal ulcer. Endoskopi Gastrointestinal, Cilt: 25 Sayı: 2, 47–48. https://ajindex.com/articles/918019

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Kim SH, Jeong JB, Kim JW, Koh SJ, Kim BG, Lee KL, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World journal of gastroenterology. [Multicenter Study Observational Study]. 2014 Aug 21;20(31):10994-9
  2. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. [Clinical Trial Research Support, Non-U.S. Gov't]. 2013 Mar;11(3):246-52 e1-5
  3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2009 Sep 17;361(12):1139-51
  4. Shibagaki K, Taniguchi H, Goto D, Kobayashi K, Kinoshita Y. Dabigatran-induced asymptomatic esophageal mucosal injury. Gastrointest Endosc. [Case Reports]. 2016 Feb;83(2):472-3; discussion 4
  5. Liu E, Shehata M, Liu T, Amorn A, Cingolani E, Kannarkat V, et al. Prevention of esophageal thermal injury during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. [Review]. 2012 Oct;35(1):35-44
  6. Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol. [Case Reports]. 2014 Jul;12(7):e55-6
  7. Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y, et al. Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016 Mar;31(3):610-4.